Switch theme
Sign up to access all valuation multiples
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Group mainly engaged in i) wholesales of pharmaceutical and healthcare products offline or online through its online platform; ii) retail of pharmaceutical and healthcare products through its retail shops; iii) operating online platform that enable the pharmaceutical distributors and vendors to sell their own pharmaceutical and healthcare products using the Group’s online platform; iv) providing SaaS solution to downstream pharmacies to streamline their inventory management; and v) providing medical testing services to primary healthcare institutions. The Group principally operates in the PRC and generates the majority of its revenues from the PRC.
2018
6.8K+
LTM Revenue $2.9B
LTM EBITDA $25.4M
$607M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
YSB has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $25.4M.
In the most recent fiscal year, YSB achieved revenue of $2.3B and an EBITDA of $19.7M.
YSB expects next 12-month revenue of XXX and NTM EBITDA of XXX
See YSB valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Profit | $296M | XXX | $231M | XXX | XXX | XXX |
| Gross Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA | $25.4M | XXX | $19.7M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| EBIT | $11.1M | XXX | -$10.7M | XXX | XXX | XXX |
| EBIT Margin | 0% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $11.5M | XXX | $1.9M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, YSB's stock price is HKD 10 (or $1).
YSB has current market cap of HKD 6.7B (or $851M), and EV of HKD 4.8B (or $607M).
See YSB trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $607M | $851M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, YSB has market cap of $851M and EV of $607M.
YSB's trades at 0.3x EV/Revenue multiple, and 30.8x EV/EBITDA.
Equity research analysts estimate YSB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
YSB has a P/E ratio of 80.2x.
See valuation multiples for YSB and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $851M | XXX | $851M | XXX | XXX | XXX |
| EV (current) | $607M | XXX | $607M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 26.0x | XXX | 30.8x | XXX | XXX | XXX |
| EV/EBIT | 59.5x | XXX | -56.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 80.2x | XXX | 442.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYSB's last 12 month revenue growth is 16%
YSB's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $36K for the same period.
YSB's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
YSB's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for YSB and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
YSB acquired XXX companies to date.
Last acquisition by YSB was XXXXXXXX, XXXXX XXXXX XXXXXX . YSB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was YSB founded? | YSB was founded in 2018. |
| Where is YSB headquartered? | YSB is headquartered in Hong Kong. |
| How many employees does YSB have? | As of today, YSB has 6.8K+ employees. |
| Who is the CEO of YSB? | YSB's CEO is Mr. Buzhen Zhang. |
| Is YSB publicy listed? | Yes, YSB is a public company listed on HKG. |
| What is the stock symbol of YSB? | YSB trades under 09885 ticker. |
| When did YSB go public? | YSB went public in 2023. |
| Who are competitors of YSB? | Similar companies to YSB include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of YSB? | YSB's current market cap is $851M |
| What is the current revenue of YSB? | YSB's last 12 months revenue is $2.9B. |
| What is the current revenue growth of YSB? | YSB revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of YSB? | Current revenue multiple of YSB is 0.2x. |
| Is YSB profitable? | Yes, YSB is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of YSB? | YSB's last 12 months EBITDA is $25.4M. |
| What is YSB's EBITDA margin? | YSB's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of YSB? | Current EBITDA multiple of YSB is 26.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
